The talcum powder lawsuit: where Johnson & Johnson's MDL stands in 2026

The Johnson & Johnson talcum powder litigation is the largest active mass tort in the U.S. federal court system. As of May 2026, more than 67,000 federal cases are pending in MDL 2738 (In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation), centralized in the U.S. District Court for the District of New Jersey before Judge Michael A. Shipp. Tens of thousands of additional cases are pending in state courts across the country, particularly in California, Missouri, New Jersey, and Pennsylvania. The total number of claims filed against J&J for alleged harm from talc-based baby powder products exceeds 90,000 across federal and state systems combined.

The litigation alleges that long-term use of J&J's talc-based products, primarily Johnson's Baby Powder and Shower-to-Shower, caused ovarian cancer and mesothelioma in plaintiffs who used the products for hygienic purposes over many years or decades. The plaintiffs' theory: the talc mined for these products was contaminated with asbestos, a known carcinogen. The litigation has been working through procedural and substantive challenges for more than a decade, with J&J pursuing settlement, bankruptcy strategies, and trial defense in parallel. The procedural posture in 2026 reflects a litigation that has moved past J&J's repeated bankruptcy attempts and into the trial and settlement phase.

This is the science underlying the talc-cancer connection, the legal framework operating across federal and state courts, the failed bankruptcy strategy and what's replacing it, the recent verdicts shaping settlement leverage, and what filings remain possible for people who may have been harmed by these products.

The science: talc, asbestos, and cancer

Talc is a naturally occurring mineral mined from the earth in close geological proximity to asbestos. The two minerals form together in many deposits, and the mining process can produce talc contaminated with asbestos fibers if the talc isn't carefully sourced from asbestos-free veins and tested for contamination. For decades, internal J&J documents (released through litigation) showed the company was aware that its talc supplies tested positive for asbestos at various points without disclosing this to consumers.

The carcinogenic connection operates through two pathways:

Direct exposure to asbestos in contaminated talc. Asbestos is classified as a known human carcinogen by the U.S. Environmental Protection Agency, the International Agency for Research on Cancer (IARC), and the National Toxicology Program. Inhalation of asbestos fibers causes mesothelioma (cancer of the mesothelium, the membrane lining the lungs, abdomen, and other organs) and various lung cancers. Talc-based products used for personal care (baby powder applied near the face, applied to underwear, used in genital areas) can result in asbestos inhalation if the talc is contaminated.

Direct exposure to talc particles in genital application. Beyond asbestos contamination, multiple epidemiological studies have associated long-term genital application of talc-based powders with increased risk of ovarian cancer. Talc particles applied near the genital area can migrate through the female reproductive tract to the ovaries, where the particles cause inflammation that has been associated with cancer development. The 2018 IARC monograph classified talc-based body powder use as "probably carcinogenic to humans" (Group 2B) for ovarian cancer.

The specific conditions linked to J&J talc product use:

Mesothelioma (pleural, peritoneal, pericardial, and testicular). The strongest scientific link, with multiple jury verdicts based on documented J&J talc use producing settlements and awards in the millions to billions of dollars per case.

Ovarian cancer, including epithelial ovarian cancer. The bulk of the J&J MDL plaintiffs allege ovarian cancer from genital application of baby powder over years or decades.

Various other cancers (endometrial, gynecological) with somewhat less developed scientific evidence but appearing in the litigation.

In January 2026, U.S. District Judge Freda Wilson issued a 685-page opinion ruling that plaintiff experts could testify about the association between talcum powder use and ovarian cancer, finding that the experts "applied reliable methodologies." This Daubert ruling is significant for the federal litigation because it clears expert testimony challenges that had been a major J&J defense strategy.

The legal framework: MDL 2738 and state court litigation

The federal litigation is consolidated in MDL 2738 before Judge Shipp. The MDL operates under the standard multidistrict litigation framework codified at 28 U.S.C. §1407. MDL consolidation centralizes pre-trial proceedings (discovery, expert challenges, common motions) for efficiency while preserving each plaintiff's individual case for trial. We cover the MDL framework generally in our overview of how mass tort settlements work.

The federal cases proceed on common legal theories: product defect (manufacturing defect from asbestos contamination, design defect from inherent talc danger, failure to warn of cancer risks). The plaintiffs allege J&J knew of cancer risks and failed to warn consumers despite decades of internal scientific knowledge.

State court litigation runs parallel to the federal MDL. Major state courts hearing talc cases include the Circuit Court of the City of St. Louis (Missouri), Los Angeles Superior Court (California), New Jersey Superior Court, and Philadelphia Court of Common Pleas (Pennsylvania). State court trials have produced the largest verdicts in the litigation because state procedural rules and damages frameworks sometimes favor plaintiffs more than federal court would.

The first federal bellwether trial in MDL 2738 remains on track for later in 2026 (the Carter Judkins case). Bellwether outcomes will substantially affect settlement negotiations across the broader litigation.

The failed bankruptcy strategy

J&J's response to talc litigation included an aggressive bankruptcy strategy designed to limit overall liability and create a structured settlement framework. The strategy used what's commonly called the "Texas Two-Step":

J&J created a subsidiary (LTL Management LLC, later replaced by Red River Talc LLC) and transferred substantially all talc-related liabilities to the subsidiary while retaining substantially all of J&J's assets and operations elsewhere. The subsidiary then filed for Chapter 11 bankruptcy, attempting to consolidate all talc claims into a bankruptcy settlement that would bind all current and future claimants.

The strategy was attempted three times:

October 2021: LTL Management filed Chapter 11 in New Jersey. The U.S. Bankruptcy Court for the District of New Jersey initially permitted the filing. In January 2023, the U.S. Court of Appeals for the Third Circuit reversed, ruling that LTL's bankruptcy was not filed in good faith because J&J itself was not in financial distress.

April 2023: J&J refiled LTL's Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey under modified terms. The court dismissed this attempt in July 2023, again finding the filing was not made in good faith.

September 2024: J&J created a new subsidiary, Red River Talc LLC, and filed Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas, hoping for a more favorable bankruptcy environment. The case was assigned to Judge Christopher Lopez. In April 2025, Judge Lopez rejected the proposed $8 billion settlement, finding that J&J "did not belong in bankruptcy proceedings" because the parent company was financially healthy.

After the April 2025 ruling, J&J announced it would not appeal and would defend the cases in court. The bankruptcy strategy is effectively closed. The litigation has resumed on the normal MDL and state court tracks.

The settlement landscape in 2026

Multiple settlement components have emerged outside the bankruptcy framework:

State Attorneys General settlement (June 2024). J&J agreed to pay $700 million to settle consumer protection claims brought by 42 states. The settlement resolved state-level claims about deceptive statements regarding talc product safety but did not resolve individual personal injury lawsuits.

Imerys Talc settlement (July 2024). J&J agreed to a $505 million settlement with Imerys Talc America (J&J's former talc supplier) and Cyprus Mines Corporation. Part of the settlement funds a bankruptcy trust to compensate current and future families affected by talc-related cancers.

Court-ordered mediation (ongoing). In September 2025, Judge Shipp appointed mediator Fouad Kurdi to facilitate settlement discussions between J&J and the MDL plaintiffs. Multiple mediation sessions have occurred through 2025 and 2026. As of May 2026, no global settlement has been reached. J&J has publicly stated it does not currently intend to offer a global settlement; mediation continues under court order.

Confidential individual settlements. J&J has settled significant numbers of individual mesothelioma cases on confidential terms outside the global structure. Most mesothelioma plaintiffs have received individual settlements; the ovarian cancer claims remain the larger pending category.

Recent verdicts shaping settlement leverage

Several recent verdicts have substantially increased plaintiffs' settlement leverage:

December 22, 2025: A Baltimore City jury returned a $1.5 billion verdict for Cherie Craft, who developed peritoneal mesothelioma after long-term J&J baby powder use. The award included approximately $59.8 million in compensatory damages and the remainder in punitive damages.

December 19, 2025: A Minnesota jury awarded $65.5 million to a mother of three with pleural mesothelioma, finding that J&J failed to warn about potential asbestos contamination.

December 16, 2025: A California jury awarded $40 million in an ovarian cancer case involving two plaintiffs.

October 2025: A California jury awarded $966 million to the family of a woman who died of mesothelioma from J&J talc use. The award was later reduced to $16 million after the trial court struck the punitive damages portion.

March 2026: A federal jury awarded $50 million in an asbestos-contaminated talc mesothelioma case.

The pattern shows substantial verdicts for plaintiffs in mesothelioma cases (where the scientific causation is well-developed) and smaller but consistent verdicts in ovarian cancer cases. The verdict landscape pressures J&J toward more comprehensive settlement negotiations because the cost of defending and losing thousands of individual cases would exceed any reasonable global settlement.

Eligibility for filing

The talc lawsuit framework remains open for new filers who meet specific criteria.

You may have a viable claim if:

You used J&J talc-based products (Johnson's Baby Powder, Shower-to-Shower, or similar products) for an extended period (typically multiple years).

You were subsequently diagnosed with ovarian cancer, mesothelioma (pleural, peritoneal, or other), or another cancer condition associated with talc exposure in the litigation framework.

The product use and diagnosis fall within the relevant statute of limitations for your state. State statutes of limitation for product liability claims typically run 2 to 4 years from the date the cause of action accrued (which courts generally interpret as the date of cancer diagnosis or the date the plaintiff knew or should have known of the connection between the product and the cancer).

You can provide documentation of product use (purchase records, family testimony, photographs, witness statements) and medical records confirming the diagnosis.

The strongest cases involve mesothelioma diagnoses (more direct causation, larger typical settlements) and well-documented long-term use of identifiable J&J talc products. Ovarian cancer cases require longer-term genital application history but are also viable.

Wrongful death claims by surviving family members. If a family member died from cancer linked to talc exposure, the estate or surviving family may have viable wrongful death claims subject to state-specific procedural requirements.

What's not eligible

Several categories don't fit the current litigation framework:

Cancers not specifically linked to talc exposure. The litigation is structured around mesothelioma and ovarian cancer (and certain related cancers). Cases involving other cancer types without an established scientific link to talc generally don't proceed.

Cases beyond the statute of limitations. State statutes of limitation are strict, and cancer cases with delayed diagnosis sometimes fall outside the filing window. The "discovery rule" in some states extends the deadline to when the plaintiff knew or should have known of the connection, but this requires fact-specific analysis.

Cases without documentable product use. Cases where the plaintiff used unspecified talc products (rather than J&J specifically), or cases without supporting documentation of product use, are difficult to prove.

Manufacturer-other-than-J&J cases. Other manufacturers of talc products may have separate litigation tracks. We cover the broader mass tort landscape including products like hair relaxers and AFFF firefighting foam where similar mass tort frameworks apply.

What to do if you may have a claim

Consult with a mass tort attorney experienced in talc cases. Most attorneys handling these cases offer free initial consultations and work on contingency, taking a percentage of any recovery rather than charging hourly fees. The attorney can evaluate whether your specific facts fit the litigation framework and whether your case is timely under the applicable statute of limitations.

Gather documentation. Medical records confirming your diagnosis. Pathology reports identifying the specific cancer type. Records of treatment, medical expenses, and lost income. Documentation of product use: receipts (often unavailable for older purchases), photographs, family testimony, witness statements. The talc product use needs to be specifically identifiable as J&J product rather than generic.

Preserve any remaining product if possible. In some cases, plaintiffs have preserved old containers of J&J talc products that can be tested for asbestos content. This evidence can be significant in proving the contamination element of the case.

Don't delay filing. State statutes of limitation are strict, and cases that aren't filed within the deadline are generally barred regardless of merit. With the bankruptcy strategy closed and the litigation in active trial and settlement phase, the timing for resolution is more favorable than it has been in years.

Consider tier of settlement versus trial. Plaintiffs whose cases are accepted into mediated settlements receive defined compensation in defined timeframes. Plaintiffs who proceed to trial may receive larger or smaller verdicts depending on the case facts; trial outcomes are inherently uncertain but recent verdicts suggest meaningful recovery is achievable for documented cases. The strategic choice depends on the specific facts and the plaintiff's risk tolerance.

The J&J talc litigation has been working through procedural and substantive challenges for more than a decade. The current phase, post-bankruptcy and into active trial and settlement, represents the most favorable posture plaintiffs have seen. For people diagnosed with cancers linked to long-term talc use, the legal framework now exists to recover for the harm; the procedural path runs through experienced counsel and the MDL or state court systems that have developed substantial expertise in handling these cases. The litigation will likely continue through 2027 and beyond before reaching final resolution, but viable claims filed now are positioned to participate in whatever settlement structure ultimately emerges.